Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 billion. While overall estimates for 2025 and beyond …

Johnson & Johnson (NYSE:JNJ) Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, expectations were $2.58. Operator: Good morning, and welcome to Johnson & Johnson’s First Quarter …

Johnson & Johnson JNJ, on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $21.89 billion, up 2.4% year over year and beating the consensus  …

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 …

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant Xarelto in the first quarter, and he is confident that this will continue through 2025 as a whole. Xarelto (rivaroxaban) fell nearly …

Johnson & Johnson's JNJ Janssen Biotech has filed a lawsuit against Samsung Bioepis, alleging the company violated a settlement agreement regarding selling a biosimilar version of Stelara, a widely used treatment for autoimmune diseases. Janssen …

Johnson & Johnson (NYSE:JNJ) Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, expectations were $1.99. Operator: Good morning and welcome to Johnson & Johnson’s Fourth …

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in …

On November 12, 2024, the drug manufacturer Johnson & Johnson (J&J) filed a lawsuit against the Health Resources and Services Administration (HRSA) in the United States District Court for the District of Columbia. The lawsuit relates to J&J’s …

When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address what it says is rampant abuse of a program originally …